Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $574.46M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.59M
Average 0.88M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
First Tracks Biotherapeutics Inc NASDAQ:TRAX | $1.98B | $47.10 | Not rated | -6.1 | — |
Cabaletta Bio, Inc. NASDAQ:CABA | $276.12M | $1.28 | Not rated | -1.8 | -56.41% |
Eledon Pharmaceuticals, Inc. NASDAQ:ELDN | $171.87M | $2.12 | Not rated | -5.5 | +28.57% |
Upstream Bio, Inc. NASDAQ:UPB | $152.38M | $2.78 | Not rated | -2.2 | -91.78% |
Continue the stock analysis
Jump to another research area for this company.